Immunomagnetic bead for chemiluminescence immunodetection as well as preparation method and application of immunomagnetic bead

By adopting a new immunomagnetic bead with core-shell structure in chemiluminescence immunoassay, the antibody coupling process is simplified, the problem of complex and inefficient coupling of traditional magnetic beads is solved, and efficient and rapid tumor marker detection is achieved, improving the Detection efficiency and sensitivity.

CN119001086AActive Publication Date: 2024-11-22FUDAN UNIVERSITY

Patent Information

Application Number
CN202410732318.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-06
Publication Date
2024-11-22
Estimated Expiration
2044-06-06

AI Technical Summary

Technical Problem

In the existing chemiluminescence immunoassay, the antibody coupling process is complex and inefficient, which affects the sensitivity and specificity of tumor marker detection. Especially when low-level marker detection, the false positive or false negative rate is high, and Traditional magnetic beads need activation treatment before antibody coupling, which affects detection efficiency.

Method used

New immunomagnetic beads with core-shell structures, including magnetic cores, epoxy shells, hydrophilic spacer arms and boric acid-based coupling layers, simplify the antibody coupling process and avoid activation steps through improved solvothermal method and click chemical reactions. , improve coupling efficiency.

Benefits of technology

Fast and efficient antibody coupling under mild conditions is achieved, the detection process is simplified, the detection time is significantly shortened, the efficiency of chemiluminescence immunoassay is improved, the false positive and false negative rates are reduced, and the antibody coupling efficiency is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119001086A_ABST
    Figure CN119001086A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological detection, and particularly relates to an immunomagnetic bead for chemiluminescence immunodetection as well as a preparation method and application of the immunomagnetic bead. The immunomagnetic bead is of a core-shell structure and comprises a magnetic inner core, an epoxy shell layer, a hydrophilic partition wall, a boric acid group coupling layer and an antibody. The preparation method comprises the following steps: firstly, preparing a magnetic inner core by utilizing a solvothermal method, polymerizing an epoxy polymer shell layer by utilizing reflux precipitation, carrying out click chemical reaction by utilizing a PEG molecule containing double-end sulfydryl and an epoxy group, modifying a hydrophilic PEG long chain, and finally, fixing a boric acid group on the surface of the microsphere through sulfydryl-double bond click chemical reaction, so as to prepare the magnetic composite microsphere. The antibody is in coordination bonding with a boric acid group on the surface of the microsphere through a cis-diol group in the structure, and is coupled to the surface of a magnetic bead carrier to obtain the chemiluminescence immunomagnetic bead. The immunomagnetic bead can be applied to detection of tumor markers, has the advantages of being simple in synthesis route, easy to operate, high in antibody coupling efficiency, high in detection sensitivity, high in specificity and the like, and achieves efficient immunodetection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological detection, and relates to immunomagnetic beads for chemiluminescent immunoassay and a preparation method and application thereof. Background Art

[0002] Early screening of cancer can greatly reduce the risk of tumor-related diseases and improve the survival rate of patients. Therefore, the development of tumor-related biomarker analysis technology with high sensitivity and specificity is crucial for the early diagnosis of tumor-related diseases. At present, a variety of analytical methods have been used to detect tumor markers in biological fluids, such as ELISA, chemiluminescent immunoassay (CLIA), electrochemiluminescent immunoassay (ECLIA), time-resolved fluorescence immunoassay, radioimmunoassay (RIA), gold-labeled immunofiltration assay and liquid chip technology. CLIA is recognized as a rapid and highly sensitive technology with the advantages of simple operation, high stability and full automation. In the clinical setting, establishing different tumor marker detection thresholds can greatly affect the false positive or false negative rate in cancer screening. It remains a challenge to achieve high sensitivity and high selectivity detection of low levels of tumor markers in serum.

[0003] CLIA based on magnetic beads is the preferred method for detecting cancer biomarkers in biological fluids. Magnetic beads are used as solid phase carriers in combination with CLIA. Under the influence of an external magnetic field, the magnetic beads can be quickly separated from the liquid matrix. These magnetic beads have efficient separation and enrichment capabilities, which can significantly reduce the effect of antigens on fixed antibodies during immunoassays. As carriers for the entire immune response and signal collection process, magnetic beads allow antigens or antibodies to be coupled and adsorbed on their chemically modified surfaces. The reactive groups on the surface of magnetic beads (including carboxyl, amino, hydroxyl and sulfate groups) provide many sites for covalently linking antigens or antibodies. Among the commercially available magnetic beads used for CLIA detection, carboxyl and tosyl magnetic beads are two commonly used commercial magnetic beads. Among them, carboxyl magnetic beads need to be activated before antibody coupling during use, while tosyl magnetic beads do not require activation treatment, but the coupling requirements are high, which will greatly affect the detection efficiency of CLIA. Therefore, the development of a new type of immunomagnetic bead that makes antibody coupling simple and efficient is crucial to improving the detection efficiency of CLIA.

[0004] Boronic acid affinity chromatography has attracted extensive research interest. Boronic acid molecules have a strong affinity for biomacromolecules containing cis-diol structures and can form stable cyclic esters with cis-diol moieties in weakly alkaline or neutral aqueous solutions. Antibodies are a type of glycoprotein that contains cis-diol groups in their domains. These characteristics suggest that borate functionalized materials are promising candidates for immunomagnetic beads that can effectively couple antibodies from the system. Summary of the invention

[0005] The primary purpose of the present invention is to provide a novel immunomagnetic bead for immunoassay, which has excellent chemiluminescent properties.

[0006] Another object of the present invention is to provide a method for preparing the above-mentioned immunomagnetic beads, which has a simple route, is easy to operate, has mild antibody coupling conditions, a short coupling time, and does not require any activation steps.

[0007] The immunomagnetic beads for immunoassay provided by the present invention are of a core-shell structure, comprising a magnetic core, an epoxy shell layer, a hydrophilic spacer arm, a boric acid coupling layer and an antibody; wherein:

[0008] The magnetic core is a magnetic nanocluster with a stabilizing agent modified on the surface, and the magnetic nanocluster is one or a mixture of γ-Fe2O3, m-γ-Fe2O3, Fe3O4;

[0009] The stabilizer is selected from polyglutamic acid, sodium citrate, oleic acid or 4-styrenesulfonic acid-co-maleic acid sodium salt; the precursor for the synthesis of magnetic nanoclusters is ferric chloride, ferric chloride hexahydrate, ferric chloride hexahydrate, ferric sulfate hydrate or ferric sulfate heptahydrate; the nucleation auxiliary agent used in the synthesis includes sodium acetate, sodium hydroxide, potassium hydroxide, and ammonium hydroxide;

[0010] The epoxy shell layer is a cross-linking functional layer with a large number of reactive epoxy functional groups;

[0011] The hydrophilic spacer arm is a single-arm or multi-arm long-chain PEG molecule containing a double-terminal thiol group in the structure;

[0012] The boric acid-based adsorption layer is a functional layer containing a large number of boric acid coordination bonds, and the boric acid groups are selected from boric acid molecules containing hydrocarbon structures;

[0013] The antibody is coupled to the surface of the magnetic bead carrier through coordination bonding between the cis-diol group in the structure and the boric acid group on the surface of the microsphere; the antibody is specifically a human monoclonal complete antibody.

[0014] In the present invention, the total particle size of the core-shell structured immunomagnetic beads is 200-500nm; the particle size of the magnetic core is 170-400nm; and the thickness of the epoxy polymer shell is 30-50nm.

[0015] The preparation method of the above-mentioned immunomagnetic beads provided by the present invention comprises the following specific steps:

[0016] Step 1, using a modified solvothermal method to prepare a surface stabilizer-modified magnetic nanoclusters in a reaction bottle to obtain a magnetic core in the form of microspheres (abbreviated as MSP);

[0017] Step 2, using reflux precipitation polymerization, a layer of cross-linked epoxy polymer is coated on the obtained microspheres as a shell layer (abbreviated as MSP@PGMA);

[0018] Step 3, using the interaction between the PEG molecules containing double-terminal thiol groups and the epoxy groups, a thiol-hydrophilic partition wall with a long PEG chain was modified (abbreviated as MSP@PGMA-SH);

[0019] Step 4, using the click chemistry reaction between the thiol group and the double bond, the boronic acid group was fixed on the surface of the microsphere (abbreviated as MSP@PGMA-PBA);

[0020] Step 5, coupling of magnetic beads and antibodies; coupling the boric acid-modified magnetic composite microspheres with antibodies in a coupling solution at a certain temperature and incubating for a certain time, and after magnetic separation, repeatedly washing twice with deionized water to obtain antibody-fixed immunomagnetic beads (abbreviated as MSP@PGMA-PBA-Ab).

[0021] Preferably, in step 1, the surface stabilizer is selected from polyglutamic acid, sodium citrate, oleic acid or 4-styrenesulfonic acid-co-maleic acid sodium salt; the reaction precursor is ferric chloride, ferric chloride hexahydrate, ferric chloride hexahydrate, ferric sulfate hydrate, ferric sulfate heptahydrate, and the nucleation auxiliary agent for the reaction includes sodium acetate, sodium hydroxide, potassium hydroxide, and ammonium hydroxide.

[0022] Preferably, in step 2, the crosslinking agent is one or more of N,N'-methylenebisacrylamide (MBA), divinylbenzene (DVB) or ethylene glycol dimethacrylate (EGDMA); preferably, the epoxy functional monomer is one or more of 2,3-epoxypropyl acrylate, (3,4-epoxycyclohexyl) methyl acrylate, 1,2-epoxy-5-hexene, 1,2-epoxy-7-octene, 3,4-epoxy-1-butene or glycidyl methacrylate (GMA).

[0023] Preferably, in step 3, the double-terminated thiol PEG molecule is one or more of SH-PEG-SH, 4Arm-PEG-SH or 8Arm-PEG-SH of different molecular weights.

[0024] Preferably, in step 4, the boronic acid coupling layer is a boronic acid group functional layer containing a large number of coordination bonds, and the boronic acid molecules are selected from molecules containing hydrocarbon groups and boronic acid structures.

[0025] Preferably, in step 5, the coupling solution is a Tris alkaline buffer solution with a pH of 7-9, the coupling temperature is 25-55°C, and the coupling time is 2-24h; the concentration of the antibody solution is 4 mg / mL, the volume ratio of the antibody to the coupling solution is 2-18:500, and the concentration of MSP@PGMA-PBA in the coupling solution is 0.5-1 mg / mL.

[0026] Furthermore, the specific process of step 1 is as follows: a certain amount of ethylene glycol is measured into a flask, and a reaction precursor and a surface stabilizer are added in sequence, and they are fully dispersed into a uniform solution by ultrasound, mechanical stirring and heating, and then a nucleation auxiliary agent is added, and heating and stirring are continued at 50 to 60°C to completely dissolve; the above solution is heated to 170 to 210°C and then reacted at a constant temperature for 12 to 16 hours. After the reaction is completed, the product is separated by magnetic adsorption, and washed with ethanol and water for multiple times, and finally the product is dispersed in deionized water, thereby obtaining stabilizer-modified magnetic core particles, recorded as MSPs.

[0027] Furthermore, in step 1, the mass ratio of the reaction precursor, the surface stabilizer, and the nucleation auxiliary agent is 1-2:8-9:9-12, and the amount of ethylene glycol used is 250-300 mL.

[0028] Furthermore, the specific process of step 2 is as follows: a certain amount of cross-linking monomer, epoxy monomer and initiator are dissolved in acetonitrile, and MSPs are dispersed in a flask containing the above mixture; the flask is connected to a condenser and reacted in an oil bath at 85-110°C for 30-90 minutes; after the reaction is completed, the product is collected by magnetic separation and washed with water and ethanol multiple times to obtain MSP@PGMA magnetic composite microspheres.

[0029] Furthermore, in step 2, the molar ratio of the crosslinking monomer to the epoxy monomer is 1:3, the amount of the initiator is 2-3 wt % of the total amount of the monomers, and the amount ratio of acetonitrile to MSP is 40-50 mL:50 mg.

[0030] Furthermore, the specific process of step 3 is as follows: the MSP@PGMA magnetic composite microspheres are uniformly dispersed in DMF, double-terminated thiol PEG molecules are added thereto, and the mixture is ultrasonically stirred for 10 minutes; DBU is placed on a microinjection pump, and DBU is added dropwise while stirring at room temperature, and the reaction is continued for 6-24 hours after the addition is completed; the product is collected by magnetic separation, and washed with ethanol several times to obtain MSP@PGMA-SH magnetic composite microspheres.

[0031] Furthermore, in step 3, the dosage ratio of DMF, MSP@PGMA, double-terminated thiol PEG molecule and DBU is 20-50 mL: 150 mg: 100-200 mg: 20 μL, and the dropping speed of DBU is 100-200 mm / h.

[0032] Furthermore, the specific process of step 4 is as follows: MSP@PGMA-SH magnetic composite microspheres are uniformly dispersed in DMF, an initiator and boric acid molecules are added thereto, and the mixture is ultrasonically stirred for 10 minutes. The reaction is stirred at 60°C for 12 to 48 hours under a nitrogen atmosphere. The product is collected by magnetic separation and washed with ethanol several times to obtain MSP@PGMA-PBA magnetic composite microspheres.

[0033] Furthermore, in step 4, the dosage ratio of DMF, MSP@PGMA-SH, boronic acid molecule and initiator is 20-50 mL: 150 mg: 100-200 mg: 6-10 mg.

[0034] Furthermore, the specific process of antibody coupling in step 5 is as follows: place the immunomagnetic beads in a 1.5 mL centrifuge tube, add coupling buffer, then add the antibody solution thereto, vortex mix for 3 minutes, place it on a constant temperature mixer at 25 to 55°C, couple the reaction for 0.5 to 8 hours, collect the product by magnetic separation, and after the reaction is completed, magnetically separate and wash the magnetic beads twice with pure water to obtain MSP@PGMA-PBA-Ab immunomagnetic beads.

[0035] Furthermore, in step 5, the concentration of the antibody solution is 4 mg / mL, the volume ratio of the antibody solution to the coupling solution is 2-18:500-1000, the concentration of MSP@PGMA-PBA in the coupling solution is 0.5-1 mg / mL, the coupling reaction temperature is 25-55° C., and the coupling time is 2-24 h.

[0036] The immune composite microspheres prepared by the present invention are of shell-core structure, and the total particle size of the magnetic beads is 200-500 nm. The particle size of the magnetic core in step 1 is 170-400 nm; and the thickness of the cross-linked polymer shell in step 3 is 30-50 nm.

[0037] The magnetic beads prepared by the invention can be used for detecting tumor markers in serum samples.

[0038] Compared with the prior art, the beneficial effects of the present invention are embodied in the following aspects:

[0039] (1) Based on the coordination bonding between the boric acid group and the cis-diol, the antibody can be quickly and efficiently coupled by adjusting the pH value of the coupling solution under mild and simple conditions. Compared with other commercial magnetic beads, it has significant advantages. For example, compared with traditional carboxyl magnetic beads, the activation steps are simplified, the operation is easier, and the process is simpler. Compared with traditional tosyl magnetic beads, the antibody coupling time is significantly reduced, which greatly shortens the detection time and is conducive to improving the efficiency of CLIA detection.

[0040] (2) The magnetic beads introduce hydrophilic spacer PEG chains, which can effectively avoid nonspecific adsorption caused by hydrophobic effects;

[0041] (3) The introduction of long-chain spacers on magnetic beads avoids the direct interaction between the boronic acid surface and the antibody to a certain extent, which is beneficial to improving the coupling efficiency of the antibody;

[0042] (4) The epoxy polymer functional layer is modified on the surface of the magnetic core by reflux precipitation, which reduces the nonspecific adsorption of the magnetic core itself and also plays a role in protecting the magnetic core, thereby improving the anti-nonspecific adsorption and acid and alkali resistance of the magnetic core;

[0043] (5) The high magnetic responsiveness makes the entire detection process simple and efficient, greatly shortening the detection time and helping to improve the efficiency of detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 This is a flow chart for the preparation of the MSP@PGMA-PBA-Ab immunomagnetic beads of the present invention.

[0045] Figure 2 The morphology and EDS element distribution spectrum of the MSP@PGMA-PBA composite microspheres prepared in Example 1 of the present invention.

[0046] Figure 3 It is a linear fitting curve of the test results of Examples 7-12 of the present invention.

[0047] Figure 4 The results are compared between the detection results of Examples 13-18 of the present invention and the luminescence intensity of commercial immunomagnetic beads for detecting different concentrations of AFP in serum. DETAILED DESCRIPTION

[0048] In order to more clearly illustrate the present invention, the present invention is further described below in conjunction with preferred embodiments. It should be clear that the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention. The present invention is further described below by specific embodiments.

[0049] Example 1: Preparation of chemiluminescent immunomagnetic beads for alpha-fetoprotein (AFP) detection.

[0050] Preparation of magnetic core microspheres. 27.06g of sodium acetate, 5.85g of ferric chloride, 9g of sodium citrate and 280mL of ethylene glycol were measured and put into a flask, and dispersed into a uniform solution by ultrasound and heating. Then, 5.4g of sodium hydroxide was added and continued to heat at 70°C for 1h to completely dissolve. The above solution was quickly heated to 200°C and reacted at a constant temperature for 9h. After the reaction, the product was magnetically separated by a magnet and washed with ethanol and water. Finally, the obtained product was dispersed in a certain amount of deionized water to obtain surface stabilizer-modified magnetic core microspheres, which were recorded as MSPs. The results of particle size analysis showed that the average particle size of the microspheres was 300nm.

[0051] The surface of the magnetic beads is coated with a functional shell containing epoxy groups. Add 250 mg MSP and 140 g acetonitrile to the reaction flask and ultrasonically disperse for 5 minutes to mix evenly. Then add 120 mg MBA, 375 mg GMA and 60 mg initiator (AIBN) to the flask in sequence, and continue ultrasonic dispersion for 10 minutes to dissolve the monomers and initiators. The flask was condensed and refluxed in a 95°C oil bath for 30 minutes. After the reaction is completed. The product was collected by magnetic separation and washed with water and ethanol several times to remove excess reactants and a small amount of polymer microspheres formed by homogeneous nucleation, and finally MSP@PGMA magnetic composite microspheres were obtained. The thickness of the shell coating layer is about 30 nm.

[0052] Modify the surface of magnetic spheres with PEG partition wall shell. Disperse 50mg MSP@PGMA magnetic spheres in 50mL DMF, add 300mg of single-arm double-terminated thiol PEG (SH-PEG-SH) with a molecular weight of 2000, stir and react at 25°C, measure 20μL of DBU, place it on a microinjection pump, set the drop speed to 100mm / h, and continue to stir and react for 24h after the drop is completed. Collect the product by magnetic separation and wash it with ethanol and water several times to remove excess SH-PEG-SH and DBU to obtain MSP@PGMA-SH magnetic composite microspheres.

[0053] The surface of the magnetic spheres was modified with boric acid groups. 25 mg of MSP@PGMA-SH magnetic spheres were dispersed in 20 mL of DMF, 150 mg of 4-vinylbenzeneboronic acid (PBA) and 3 mg of AIBN were added, and the spheres were placed in an oil bath at 60 °C and reacted for 48 h under nitrogen protection. After the reaction was completed, the product was collected by magnetic separation and washed several times with ethanol and water to finally obtain magnetic beads MSP@PGMA-PBA. The morphology and element distribution of the magnetic beads are shown in Figure 2. Figure 2 As shown in (a) and (b).

[0054] Magnetic beads coupled to AFP antibody. 3.6 mg of the prepared magnetic beads were dispersed in a 1.5 mL centrifuge tube, 1 mL of pH = 8 coupling buffer was added thereto, and then 18 μL of AFP antibody was added thereto, vortexed for 3 min, and placed on a constant temperature mixer at 37 ° C. The coupling reaction was carried out for 2 h, and the product was collected by magnetic separation and washed twice with deionized water to obtain MSP@PGMA-PBA-Ab.

[0055] Example 2: This example is basically the same as Example 1, except that: during the preparation of the surface-modified thiol groups of the magnetic spheres, the SH-PEG-SH molecules with a molecular weight of 2000 are replaced with SH-PEG-SH molecules with a molecular weight of 200, and the concentration of thiol groups in the mixed solution remains unchanged.

[0056] Example 3: This example is basically the same as Example 1, except that: during the preparation of the surface-modified thiol groups of the magnetic spheres, the SH-PEG-SH molecules with a molecular weight of 2000 were replaced with SH-PEG-SH molecules with a molecular weight of 8000, and the concentration of thiol groups in the mixed solution remained unchanged.

[0057] Example 4: This example is basically the same as Example 1, except that: during the preparation of the surface-modified thiol groups of the magnetic spheres, the SH-PEG-SH molecules with a molecular weight of 2000 were replaced with four-arm SH-PEG-SH molecules with a molecular weight of 2000, and the concentration of thiol groups in the mixed solution remained unchanged.

[0058] Example 5: This example is basically the same as Example 1, except that: during the preparation of the thiol groups on the surface of the magnetic sphere, the SH-PEG-SH molecule with a molecular weight of 2000 is replaced with an eight-arm SH-PEG-SH molecule with a molecular weight of 2000, and the concentration of the thiol groups in the mixed solution remains unchanged.

[0059] Example 6: This example is basically the same as Example 1, except that: during the preparation of the boron groups modified on the surface of the magnetic spheres, 4-vinylphenylboronic acid is replaced with 2-vinylphenylboronic acid, and the concentration of the boronic acid groups in the mixed solution remains unchanged.

[0060] Example 7: The immunomagnetic beads prepared in Example 1 were used for the detection of AFP standards.

[0061] Place the MSP@PGMA-PBA-Ab magnetic beads in a 1.5 mL centrifuge tube, add 1 mL of blocking buffer (1% BSA-PBS buffer), vortex mix for 3 minutes, then place it on a constant temperature mixer at 37°C, block the reaction for 3 hours, collect the product by magnetic separation, and wash it twice with blocking buffer to obtain MSP@PGMA-PBA-Ab-BSA magnetic composite microspheres.

[0062] The above-mentioned MSP@PGMA-PBA-Ab-BSA magnetic composite microspheres were dispersed in 3 mL of blocking buffer. A mixed solution with a concentration of 1.2 mg / mL was prepared. 200 μL of the mixed solution was taken, and 1.8 mL of blocking buffer was added to dilute it. The diluted sample was added to the sampling slot 1 of the detection instrument, and 3 mL of AFP-labeled monoclonal antibody (referred to as Ab-ALP) was added to the sample slot 2. 1 mL of 10 ng / mL AFP standard was added to the sample slot of the instrument, and 20 mL of luminescent substrate solution (AMPPD solution) was added to the injection slot. The injection volumes of AFP samples, enzyme-labeled antibodies, and luminescent substrates were set to 100 μL / time, 50 μL / time, and 200 μL / time, respectively. In the instrument parameter interface, the detection time of the AFP sample was set to 30 min, the reaction time of the magnetic beads and the enzyme-labeled antibodies after coupling the AFP sample was set to 30 min, and the incubation time with the reaction substrate was set to 30 min. Finally, the instrument was started for detection.

[0063] Example 8: This example is basically the same as Example 7, except that the concentration of the AFP-containing sample added to the sample tank is changed from an AFP standard sample with a concentration of 10 ng / mL to an AFP standard sample with a concentration of 5 ng / mL.

[0064] Example 9: This example is basically the same as Example 7, except that the concentration of the AFP-containing sample added to the sample tank is changed from an AFP standard sample with a concentration of 10 ng / mL to an AFP standard sample with a concentration of 2.5 ng / mL.

[0065] Example 10: This example is basically the same as Example 7, except that the concentration of the AFP-containing sample added to the sample tank is changed from 10 ng / mL AFP standard to 1.25 ng / mL AFP standard.

[0066] Example 11: This example is basically the same as Example 7, except that the concentration of the AFP-containing sample added to the sample tank is changed from an AFP standard sample with a concentration of 10 ng / mL to an AFP standard sample with a concentration of 0.625 ng / mL.

[0067] Example 12: This example is basically the same as Example 7, except that the concentration of the AFP-containing sample added to the sample tank is changed from the AFP standard sample with a concentration of 10 ng / mL to a sample without AFP.

[0068] The results of Examples 7-12 were further analyzed, and the concentration and chemiluminescence intensity were curve fitted. Figure 3 shown.

[0069] Depend on Figure 3 It can be seen that at a lower AFP detection concentration, the AFP concentration to be detected (C) and the luminescence intensity (I) increase linearly, and the fitting curve satisfies I=22728C+678. Example 12 was tested 20 times with repeatability, and the results are shown in Table 1 below. The standard deviation of the 20 test results (denoted as S) was calculated, and the minimum detection limit was calculated based on the concentration of three times the signal-to-noise ratio. It was concluded that the minimum detection limit of AFP by MSP@PGMA-PBA-Ab magnetic composite microspheres was 1.2 pg / mL.

[0070] Table 1 Chemiluminescence intensity results of Example 12 Repeatability test 20 times

[0071] Number of detections Relative luminous intensity 1 686 2 674 3 672 4 679 5 667 6 698 7 699 8 672 9 676 10 680 11 682 12 684 13 686 14 688 15 690 16 692 17 694 18 696 19 698 20 672 .

[0072] Example 13: This example is basically the same as Example 7, except that the type of AFP-containing sample added to the sample tank is replaced by a serum sample containing 500 ng / mL AFP from a pure AFP sample with a concentration of 10 ng / mL.

[0073] Example 14: This example is basically the same as Example 7, except that the type of the AFP-containing sample added to the sample tank is replaced by a serum sample containing 250 ng / mL AFP instead of a pure AFP sample with a concentration of 10 ng / mL.

[0074] Example 15: This example is basically the same as Example 7, except that the type of AFP-containing sample added to the sample tank is replaced by a serum sample containing 50 ng / mL AFP from a pure AFP sample with a concentration of 10 ng / mL.

[0075] Example 16: This example is basically the same as Example 7, except that the type of AFP-containing sample added to the sample tank is replaced by a serum sample containing 25 ng / mL AFP from a pure AFP sample with a concentration of 10 ng / mL.

[0076] Example 17: This example is basically the same as Example 7, except that the type of AFP-containing sample added to the sample tank is replaced by a serum sample containing 5 ng / mL AFP from a pure AFP sample with a concentration of 10 ng / mL.

[0077] Example 18: This example is basically the same as Example 7, except that the type of AFP-containing sample added to the sample tank is replaced by a serum sample without AFP from a pure AFP sample with a concentration of 10 ng / mL.

[0078] The results of Examples 13-18 were further analyzed and compared with the detection effects of other commercial immunomagnetic beads (IMB). The comparative data results are shown in Figure 4 shown.

[0079] Depend on Figure 4 The results show that as the AFP concentration in the sample increases, the chemiluminescence intensity gradually increases. This shows the feasibility of detection in serum. Compared with other commercial IMBs, it has a stronger luminescence intensity at high AFP detection concentrations, showing better detection performance.

Claims

1. An immunomagnetic bead for chemiluminescent immunoassay, characterized in that: It is a core-shell structure, including a magnetic core, an epoxy shell, a hydrophilic spacer arm, a boric acid coupling layer and an antibody; wherein: The magnetic core is a magnetic nanocluster with a stabilizing agent modified on the surface, and the magnetic nanocluster is one or a mixture of γ-Fe2O3, m-γ-Fe2O3, Fe3O4; The stabilizer is selected from polyglutamic acid, sodium citrate, oleic acid or 4-styrenesulfonic acid-co-maleic acid sodium salt; the precursor for the synthesis of magnetic nanoclusters is ferric chloride, ferric chloride hexahydrate, ferric chloride hexahydrate, ferric sulfate hydrate or ferric sulfate heptahydrate; the nucleation auxiliary agent used in the synthesis is selected from sodium acetate, sodium hydroxide, potassium hydroxide, ammonium hydroxide; The epoxy shell layer is a cross-linking functional layer with a large number of reactive epoxy functional groups; The hydrophilic spacer arm is a single-arm or multi-arm long-chain PEG molecule containing a double-terminal thiol group in the structure; The boric acid-based adsorption layer is a functional layer containing a large number of boric acid coordination bonds, and the boric acid groups are selected from boric acid molecules containing hydrocarbon structures; The antibody is coupled to the surface of the magnetic bead carrier through coordination bonding between the cis-diol group in the structure and the boric acid group on the surface of the microsphere; the antibody is specifically a human monoclonal complete antibody.

2. The immunomagnetic beads for chemiluminescent immunoassay according to claim 1, characterized in that: The total particle size of the core-shell structured immunomagnetic beads is 200-500 nm; the particle size of the magnetic core is 170-400 nm; and the thickness of the epoxy polymer shell is 30-50 nm.

3. The method for preparing immunomagnetic beads according to claim 1 or 2, characterized in that: The specific steps are: Step 1, using a modified solvothermal method to prepare a surface stabilizer-modified magnetic nanoclusters in a reaction bottle to obtain a magnetic core in the form of microspheres, denoted as MSP; the surface stabilizer is selected from polyglutamic acid, sodium citrate, oleic acid or 4-styrenesulfonic acid-co-maleic acid sodium salt; the reaction precursor is ferric chloride, ferric chloride hexahydrate, ferric chloride hexahydrate, ferric sulfate hydrate or ferric sulfate heptahydrate, and the reaction nucleation auxiliary agent is selected from sodium acetate, sodium hydroxide, potassium hydroxide, and ammonium hydroxide; Step 2, using reflux precipitation polymerization to coat the obtained microspheres with a layer of cross-linked epoxy polymer as a shell layer, and the product is recorded as MSP@PGMA; the cross-linking agent used is one or more of N,N'-methylenebisacrylamide (MBA), divinylbenzene (DVB) or ethylene glycol dimethacrylate (EGDMA); Step 3, using a PEG molecule containing a double-terminal thiol group to interact with an epoxy group to modify a thiol-hydrophilic spacer with a long PEG chain, and the product is recorded as MSP@PGMA-SH; the double-terminal thiol group-containing PEG molecule is one or more of SH-PEG-SH, 4Arm-PEG-SH or 8Arm-PEG-SH with different molecular weights; Step 4, using the click chemistry reaction between the thiol group and the double bond, the boronic acid group is fixed on the surface of the microsphere, and the product is recorded as MSP@PGMA-PBA; the boronic acid molecule is selected from molecules containing hydrocarbon groups and boronic acid structures; Step 5, coupling of magnetic beads with antibodies; specifically, coupling the boric acid-modified magnetic composite microspheres with antibodies in a coupling solution at a certain temperature for a period of time, and then washing them twice with deionized water after magnetic separation to obtain antibody-fixed immunomagnetic beads, recorded as MSP@PGMA-PBA-Ab; wherein the coupling solution is a Tris alkaline buffer solution with a pH of 7-9, the coupling temperature is 25-55°C, and the coupling time is 2-24h; the concentration of the antibody solution is 4mg / mL, the volume ratio of the antibody to the coupling solution is 2-18:500, and the concentration of MSP@PGMA-PBA in the coupling solution is 0.5-1mg / mL.

4. The method for preparing immunomagnetic beads according to claim 3 is characterized in that the specific process of step 1 is as follows: ethylene glycol is placed in a flask, and a reaction precursor and a surface stabilizer are added in sequence, and the precursors and the surface stabilizers are fully dispersed into a uniform solution by ultrasound, mechanical stirring and heating, and then a nucleation auxiliary agent is added, and heating and stirring are continued at 50 to 60° C. to completely dissolve the solution; the solution is heated to 170 to 210° C. and then reacted at a constant temperature for 12 to 16 hours. After the reaction is completed, the product is separated by magnetic adsorption, and washed with ethanol and water for multiple times, and finally the product is dispersed in deionized water, thereby obtaining stabilizer-modified magnetic core particles, which are recorded as MSPs; The mass ratio of the reaction precursor, the surface stabilizer and the nucleation auxiliary agent is (1-2):(8-9):(9-12), and the amount of ethylene glycol used is 250-300 mL.

5. The method for preparing immunomagnetic beads according to claim 3 is characterized in that the specific process of step 2 is as follows: dissolving the cross-linking monomer, epoxy monomer and initiator in acetonitrile, and dispersing MSPs in a flask containing the above mixture; connecting the flask to a condenser, and reacting in an oil bath at 85-110° C. for 30-90 minutes; after the reaction is completed, collecting the product by magnetic separation, and washing it with water and ethanol for multiple times to obtain MSP@PGMA magnetic composite microspheres; The molar ratio of the cross-linking monomer to the epoxy monomer is 1:3, the amount of the initiator is 2-3wt% of the total amount of the monomers, and the amount ratio of acetonitrile to MSP is 40-50mL:50mg.

6. The method for preparing immunomagnetic beads according to claim 3 is characterized in that the specific process of step 3 is as follows: MSP@PGMA magnetic composite microspheres are uniformly dispersed in DMF, double-terminated thiol PEG molecules are added thereto, and ultrasonic stirring and mixing are performed for 10 minutes; DBU is placed on a microinjection pump, and DBU is added dropwise while stirring at room temperature, and the reaction is continued for 6-24 hours after the addition is completed; the product is collected by magnetic separation, and washed with ethanol for multiple times to obtain MSP@PGMA-SH magnetic composite microspheres; in, The dosage ratio of DMF, MSP@PGMA, double-terminated thiol PEG molecules and DBU is (20-50 mL):150 mg:(100-200 mg):20 μL, and the dropping speed of DBU is 100-200 mm / h.

7. The method for preparing immunomagnetic beads according to claim 3 is characterized in that the specific process of step 4 is as follows: MSP@PGMA-SH magnetic composite microspheres are uniformly dispersed in DMF, an initiator and boric acid molecules are added thereto, and ultrasonic stirring and mixing are performed for 10 minutes; stirring and reacting at 60° C. for 12 to 48 hours under a nitrogen atmosphere; collecting the product by magnetic separation, and washing it with ethanol for multiple times to obtain MSP@PGMA-PBA magnetic composite microspheres; in, The dosage ratio of DMF, MSP@PGMA-SH, boric acid molecule and initiator is (20-50 mL):150 mg:(100-200 mg):(6-10 mg).

8. The method for preparing immunomagnetic beads according to claim 3 is characterized in that the specific process of antibody coupling in step 5 is as follows: place the immunomagnetic beads in a 1.5 mL centrifuge tube, add coupling buffer, then add the antibody solution thereto, vortex mix for 3 minutes, place it on a constant temperature mixer at 25 to 55° C., couple the reaction for 0.5 to 8 hours, collect the product by magnetic separation, and after the reaction is completed, magnetically separate and wash the magnetic beads twice with pure water to obtain MSP@PGMA-PBA-Ab immunomagnetic beads.

9. The method for preparing immunomagnetic beads according to claim 8, wherein the concentration of the antibody solution in step 5 is 4 mg / mL, the volume ratio of the antibody solution to the coupling solution is (2-18):(500-1000), the concentration of MSP@PGMA-PBA in the coupling solution is 0.5-1 mg / mL, the coupling reaction temperature is 25-55°C, and the coupling time is 2-24 h.

10. Use of the immunomagnetic beads as claimed in claim 1 or 2 in the detection of tumor markers.

Citation Information

Patent Citations

  • Polymer chemiluminescent labeling reagent as well as preparation method and application of reagent

    CN103792346A

  • Immunomagnetic bead, preparation method and application thereof

    CN104914241A

  • Preparation method of high-stability magnetic beads

    CN115856286A

  • Ionic magnetic bead for extracting and purifying DNA as well as preparation method and application of ionic magnetic bead

    CN116272903A

  • Modified immunomagnetic bead as well as preparation method and application thereof

    CN118307681A

Cited By

  • Cross-linked hydrophilic coating magnetic microsphere as well as preparation method and application thereof

    CN119455921A

  • Preparation method of sandwich type immunomagnetic beads with high thermal stability

    CN119534832A

  • Magnetic bead and method for detecting glycosylated tumor markers

    CN119846198A

  • A magnetic bead and method for detecting glycosylated tumor marker

    CN119846198B